HMB is one of the most common symptoms requiring investigation and treatment. The NICE HMB Guideline first produced in 2007 has been substantially revised in line with recent innovations and the accumulated evidence.
The updated NICE guideline was published in February 2018 and impacts on clinical practice in both primary and secondary care.
Some of the new recommendations have been considered controversial.
The BSGE has put together this meeting to cover the contemporary management of HMB and its implementation within the context of the new NICE guideline.
The meeting includes a range of speakers: Some who contributed to the guideline, some who criticised it and others who have provided major contributions to the scientific literature in HMB.
Date and Venue:
Friday, 7th December 2018
Nuffield Hall, Royal College of Obstetricians and Gynaecologists,
27 Sussex Place Regent’s Park, London, NW1 4RG, UK
You can download the meeting programme here.
Presentations from speakers can be found in pdf format below.
Endometrial Ablation for Heavy Menstrual Bleeding- Jonathan Lord
Managing ‘bleeding problems’ in primary care- Anne Connolly
Medical and surgical management of fibroids (excluding hysterectomy)- Ertan Saridogan
Treating Uterine Fibroids- Medical Management in Practice- Ertan Saridogan
Which hysterectomy for HMB- Ray Garry
Management of HMB in women with haematological disease and other medical disorders- Rezan A Kadir
Investigating HMB- an evidence based approach- Justin Clark
Clinical uncertainties in HMB- What research is needed- Justin Clark
BSGE wishes to express its sincere gratitude and appreciation to sponsors of this meeting and for their continuing support of the society.
The company was founded in 1901 by Hungarian pharmacist Gedeon Richter. Today Richter has grown to become a multinational pharmaceutical company with headquarters in Budapest. The company’s products are distributed in more than 100 countries and it employs around 11,000 people worldwide. Innovation and the research of original drug molecules have always been key elements in the Company’s strategy. The Women’s Health Division of Richter is dedicated to the development and commercialisation of innovative drugs for women’s reproductive medicine. R&D activities within Women’s Health focus on developing non-invasive medical treatments for common gynaecological conditions which are currently under-treated. Many of these conditions can have a severe impact on the patient’s quality of life. The company has a pipeline of innovative compounds which includes several first in class molecules with development stages spanning from pre-clinical to newly licensed.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic leads the industry in digital mammography systems and offers the most advanced technology for breast imaging and intervention.
Hologic is committed to enhancing women’s lives through earlier detection, improved diagnosis and less invasive treatments. Core business units are focused on mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, polyps and fibroids, osteoporosis assessment, preterm birth screening, and mini C-arm and extremity MRI imaging for orthopedic applications.
Kebomed offers innovative, tailored and cost effective solutions, which reflect the needs of the local healthcare system. We provide tailored solutions to medical device manufacturers wishing to develop and grow their business, providing one contact across all of Europe.We strive to be the preferred point of contact and the first choice of both our customers and our suppliers for medical products across Europe.